Pharmacologic advances in the treatment of schizophrenia

被引：10

作者：

Keith, SJ

机构：

来源：

NEW ENGLAND JOURNAL OF MEDICINE | 1997年 / 337卷 / 12期

关键词：

D O I：

10.1056/NEJM199709183371211

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：851 / 852

页数：2

共 6 条

[1] Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].

Beasley, CM ;

Tollefson, G ;

Tran, P ;

Satterlee, W ;

Sanger, T ;

Hamilton, S ;

Fabre, L ;

Small, J ;

Ereshefsky, L ;

True, J ;

Nemeroff, C ;

Risch, SC ;

Perry, PJ ;

Potkin, SG ;

Borison, RL ;

James, S ;

Meltzer, HY ;

Iqbal, N ;

Fann, WE ;

Gewirtz, GR ;

Landbloom, R ;

RoyByrne, PP ;

Tuason, VB ;

Carman, JS ;

Stokes, PE ;

Williams, R ;

Ancill, RJ ;

MacEwan, GW ;

Gujavarty, KS ;

Jones, B ;

Lohr, JB .

NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123

[2]

CARLSSON A, 1963, ACTA PHARMACOL TOX, V20, P140

[3]

KANE J, 1988, ARCH GEN PSYCHIAT, V45, P789

[4]

MARDER SR, 1994, AM J PSYCHIAT, V151, P825

[5] A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia [J].

Rosenheck, R ;

Cramer, J ;

Xu, WC ;

Thomas, J ;

Henderson, W ;

Frisman, L ;

Fye, C ;

Charney, D .

NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (12) :809-815

[6]

Zimbroff DL, 1997, AM J PSYCHIAT, V154, P782

← 1 →